Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)												1 Months Ended		3 Months Ended	9 Months Ended
Equity (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 05, 2017	Jun. 21, 2017	Jun. 21, 2017	Jun. 16, 2017	Apr. 18, 2017	Mar. 22, 2017	Mar. 22, 2017	Feb. 08, 2017	Jan. 25, 2017	Jan. 06, 2017	Feb. 28, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Jul. 07, 2017	Oct. 31, 2014
Gross proceeds from equity offerings	$ 960,000														$ 27,900,000
Number of common stock issued, shares				9,900,000
Proceeds from issuance of common stock															24,042,000
Warrants to purchase shares of common stock	875,000
Proceeds from issuance or sale of equity															27,900,000
Fair value of warrants issued														$ 200,000	$ 401,000
Option to purchase overallotment option, percentage					4.00%
Warrant term		3 years													5 years
Debt conversion, converted instrument, amount															$ 11,643,000
Underwriters over allotment option to purchase common stock	875,000				1,875,000
Debt instrument beneficial percentage, description															The company offered to each purchaser whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding common stock. Subject to limited exceptions, a holder of pre-funded warrants could not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each pre-funded warrant was exercisable for one share of our common stock.
Warrant exercise price		$ 1.25
Underwriters purchase common stock, value	$ 960,000
Proceeds from warrants															$ 193,000
Payments for services		$ 200,000
Warrant expiring date		Aug. 31, 2020
Warrants exercisable into common stock		150,000
Underwriter Discount [Member] \| July 31, 2017 [Member]
Underwriters purchase common stock, value														72,000	72,000
Proceeds from warrants															882,000
RedPath Note [Member]
Repayments of debt													$ 1,330,000
Debt instrument principal amount													9,340,000					$ 1,070,000
RedPath Note [Member] \| Senior Secured Non-Convertible Note [Member]
Debt instrument principal amount						$ 3,550,000								$ 3,550,000	$ 3,550,000
Debt conversion, converted instrument, amount						$ 3,550,000
Debt conversion, converted instrument, shares issued						3,795,429
RedPath Note [Member] \| Investor [Member]
Acquitision of debt								$ 8,870,000
RedPath Note [Member] \| RedPath Integrated Pathology, Inc [Member]
Debt instrument principal amount													9,340,000
Senior Secured Convertible Note [Member]
Debt instrument principal amount													5,320,000
Senior Secured Non-Convertible Note [Member]
Debt instrument principal amount													$ 3,550,000
Termination Agreement [Member] \| RedPath Equityholder Representative [Member]
Warrants to purchase shares of common stock							100,000	100,000
Common stock purchase price per share							$ 4.69	$ 4.69
Fair value of warrants issued							$ 190,000
Warrant term							5 years
Employee Severance [Member]
Payments for restructuring												$ 1,000,000
Second Registered Direct Offering [Member]
Number of common stock issued, shares											630,000
Commo stock price, per share											$ 6.81
Proceeds from issuance of common stock											$ 4,200,000
Third Registered Direct Offering [Member]
Number of common stock issued, shares										855,000
Fair value of warrants issued										$ 1,670,000
Third Registered Direct Offering [Member] \| Employee Severance [Member]
Payments for restructuring										$ 1,000,000
Third Registered Direct Offering [Member] \| Private Placement [Member]
Warrants to purchase shares of common stock										855,000
Common stock purchase price per share										$ 4.69
Proceeds from issuance or sale of equity										$ 4,000,000
Confidentially Marketed Public Offering (CMPO) [Member]
Number of common stock issued, shares									1,200,000
Commo stock price, per share									$ 3.00
Proceeds from issuance or sale of equity									$ 3,900,000
Option to purchase overallotment option, percentage									9.00%
Common Stock [Member]
Number of common stock issued, shares															34,000
Warrants to purchase shares of common stock					9,900,000
Base Warrants [Member]
Gross proceeds from equity offerings				$ 13,700,000
Number of common stock issued, shares				12,500,000
Warrants to purchase shares of common stock					12,500,000
Common stock purchase price per share					$ 1.25
Fair value of warrants issued				$ 5,300,000
Common stock effective purchase price					$ 1.10
Underwriters over allotment option to purchase common stock					1,875,000
Underwriter Warrants[Member]
Number of common stock issued, shares			575,000
Warrants to purchase shares of common stock					2,600,000
Common stock purchase price per share					$ 0.01
Warrant exercise price			$ 0.01	$ 0.01										$ 1.32	$ 1.32
Base Warrant And Prefunded Warrants [Member]
Common stock effective purchase price					$ 1.09
Oveallotment Warrants [Member]
Warrants to purchase shares of common stock			1,875,000	1,875,000
Common stock purchase price per share			$ 0.01	$ 0.01
Prefunded Warrants [Member]
Gross proceeds from equity offerings				$ 12,300,000
Number of common stock issued, shares				2,600,000
Warrants to purchase shares of common stock					2,600,000												2,600,000
Common stock purchase price per share					$ 1.09
Underwriting discount rate					7.50%
Offering and over-allotment and reasonable out-of-pocket expenses					$ 100,000
Warrant exercised																	2,600,000
Warrant exercise price			$ 1.09	$ 1.09	$ 1.09									$ 0.01	$ 0.01		$ 0.01
Overallotment Warrants [Member]
Number of common stock issued, shares			1,875,000
Fair value of warrants issued			$ 800,000